ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

CORRECT(12/13): FDA Panel Recommends Use Of Alexza Pharma's Bipolar Treatment

("FDA Panel Recommends Use Of Alexza Pharma's Bipolar Treatment" on Dec. 13 and an earlier story on Jan. 18 misstated that Valeant Pharmaceuticals International Inc. is currently a commercial partner for the drug. A corrected version follows:) DOW JONES NEWSWIRES Alexza Pharmaceuticals Inc. (ALXA) said a U.S. Food and Drug Administration panel has recommended that its schizophrenic and bipolar disorder treatment be approved for use. Shares were recently up 76% to $1.10 as the company's chief executive called the panel's recommendation "another step forward" for the drug's development. Alexza in August said it refiled its new drug application for the treatment, adding new data and sections that aimed to address safety concerns raised by the agency last year. "If approved, we believe Adasuve represents a valuable treatment option for patients and physicians alike. We look forward to continuing to work toward our goal of bringing Adasuve to market in 2012," said Chief Executive Thomas B. King. Alexza last month reported its third-quarter loss widened sharply from a year earlier as it recorded higher research and development expenses and a loss on a contingent liability. -By Mia Lamar, Dow Jones Newswires; 212-416-3207; mia.lamar@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
04/23/201409:12:27Ackman: Poison Pill Is Way for Allegan to Explore Alternatives...
04/22/201420:09:21Allergan Pursuer Valeant: A Drug Maker With Little Patience for...
04/22/201418:18:04Valeant Pharmaceuticals Is a Popular Play Among Hedge Funds...
04/22/201417:30:11MARKET SNAPSHOT: U.S. Stocks Gain; S&P 500 Extends Streak To...
04/22/201415:04:46Ackman Warns Allergan Against Saying No to Valeant Offer
04/22/201414:38:17MARKET SNAPSHOT: U.S. Stocks Rise; Netflix Jumps On Results
04/22/201413:44:03Novartis Overhauls Portfolio With Deals Worth $25 Billion...
04/22/201413:36:50Valeant, Ackman Propose Allergan Deal -- 7th Update
04/22/201412:11:36ValueAct CEO: Allergan and Valeant are Perfect Match -CNBC
04/22/201411:59:49Valeant, Ackman Propose Allergan Deal -- 6th Update
04/22/201410:23:35Valeant, Ackman Propose Allergan Deal -- 5th Update
04/22/201409:43:08U.S. Hot Stocks: Hot Stocks to Watch
04/22/201408:44:13Valeant, Ackman Propose Allergan Deal -- 4th Update
04/22/201406:21:34AstraZeneca Helps Boost European Shares
04/07/201403:39:11Meda and Valeant Terminate Joint Ventures
03/13/201417:52:06Anacor Pharmaceuticals Swings to a Profit
01/14/201406:11:37Valeant, Actavis, Mylan Said Interested in Buying Pfizer's Generics...
12/16/201309:15:12U.S. Hot Stocks Futures: Hot Stocks to Watch
12/16/201309:00:06Valeant to Acquire Solta Medical for $250 Million
11/15/201309:18:02OZ Management LP 3Q 13F: Holdings As Of Sep 30 -2-

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad